减弱中和,保持特异性:在脏杂种移植接受者中对SARS-CoV-2助推剂的幽默反应
Martina Fialova1, Eva Cecrdlova1, Ivan Zahradka2
1Department of Clinical and Transplant Immunology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Diagnostic microbiology and infectious disease
|October 22, 2024
概括
移植接受者 (KTRs) 显示在COVID-19增剂接种疫苗后,中和抗体的减少和更快的下降. 年龄和免疫抑制等因素会影响抗体水平,但特异性仍然与健康个体相比.
科学领域:
- 免疫学 免疫学 免疫学
- 腎臟病學 (nephrology) 是一種醫學.
- 病毒学 病毒学
背景情况:
- 移植接受者 (KTRs) 尽管接种了广泛的疫苗和先前感染,但仍然容易受到COVID-19的感染.
- 当前的SARS-CoV-2变种虽然病毒性较低,但对像KTRs这样的免疫受损人群仍然构成重大风险.
研究的目的:
- 为了评估KTRs中抗SARS-CoV-2抗体生产参数后补丁疫苗接种.
- 确定影响中和抗体水平和KTRs中的动力学因素.
主要方法:
- 这项研究涉及120名接受脏移植的接受者,他们接受了BNT162b2 mRNA COVID-19疫苗增剂.
- 评估了抗体水平,中和能力和针对SARS-CoV-2抗原的特异性.
- 分析了与临床因素的相关性,包括年龄,估计的淋巴细胞过率 (eGFR) 和免疫抑制药物 (mycophenolate mofetil).
主要成果:
- 与健康受试者相比,KTRs表现出明显较低的产生和中和抗体的更快下降.
- 年龄,较低的eGFR和全剂量mycophenolate mofetil与降低的抗体反应有关.
- 中和抗体与向SARS-CoV-2受体结合域 (RBD) 和尖端蛋白的抗体相关,以及SARS-CoV-1,但不是季节性冠状病毒.
结论:
- KTRs对SARS-CoV-2增强疫苗接种表现出受损的幽默免疫反应,其特点是降低中和抗体的产生和加速衰变.
- 免疫抑制和患者特异性因素显著降低了KTRs中的抗体反应.
- 尽管存在定量差异,但KTRs中的抗体反应的定性特异性与健康个体的特异性相当.
相关概念视频
Cell-mediated Immune Responses
67.4K
Overview
67.4K
Kidney Transplant I: Introduction
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
Kidney Transplant II: Surgical Procedure
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
Cross-reactivity
31.0K
Overview
31.0K


